Griseofulvin
Griseofulvin is an oral antifungal medication used to treat ringworm infections of the skin, hair, and nails caused by specific dermatophyte fungi.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 9 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Griseofulvin: Patient Information Guide
A plain-language walkthrough of Griseofulvin — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Griseofulvin is an oral antifungal that treats dermatophyte (ringworm-type) fungal infections across several products and formulations. It is used when topical (skin-applied) treatments alone are not adequate.
- Tinea corporis — ringworm of the body
- Tinea pedis — athlete's foot
- Tinea cruris — jock itch (ringworm of the groin and thigh)
- Tinea barbae — ringworm of the beard area
- Tinea capitis — ringworm of the scalp
- Tinea unguium (onychomycosis) — fungal infection of the fingernails or toenails
Griseofulvin does not work against bacterial infections, yeast infections (candidiasis), or other fungal infections such as histoplasmosis, sporotrichosis, tinea versicolor, or cryptococcosis. A confirmed fungal diagnosis — through lab testing such as a KOH preparation, fungal culture, or nail biopsy — should be obtained before starting treatment.
⚙️How it works▾
Griseofulvin stops dermatophyte fungi from multiplying by binding to proteins called microtubules inside fungal cells. Microtubules are essential for cell division (mitosis); when griseofulvin blocks them, the fungus can no longer reproduce and spread. After you take it by mouth, the drug is absorbed and deposits into keratin precursor cells — the building blocks of new skin, hair, and nail tissue — making that new tissue resistant to fungal invasion as it grows in.
Griseofulvin has no effect on bacteria or fungal species outside the dermatophyte group it targets. There have been reports of dermatophyte resistance to griseofulvin, though the clinical importance of this is not fully established.
💊How it's taken▾
Griseofulvin is taken by mouth, once or twice daily depending on the product and the infection being treated. Taking it with a fatty meal — such as one containing milk or other high-fat foods — significantly boosts absorption and is generally recommended. Ultramicrosize Griseofulvin tablets may be swallowed whole or crushed and mixed into a tablespoon of applesauce and swallowed right away. Treatment courses vary considerably by infection site:
- Tinea capitis (scalp): typically 4 to 6 weeks
- Tinea corporis (body): typically 2 to 4 weeks
- Tinea pedis (athlete's foot): typically 4 to 8 weeks
- Tinea unguium (nails): fingernails at least 4 months; toenails at least 6 months
Always follow your prescriber's instructions and complete the full course — stopping early is very likely to cause the infection to return.
🤒Side effects — in detail▾
The most common side effects with griseofulvin are hypersensitivity (allergic-type) reactions and stomach-related symptoms. Serious reactions have also been reported, though they are less common.
- Skin rash or hives
- Nausea, vomiting, or upset stomach
- Diarrhea
- Headache
- Dizziness or fatigue
- Insomnia
- Tingling or numbness in the hands and feet (peripheral neuropathy — more likely with longer treatment)
- Oral thrush (yeast infection in the mouth)
Stop griseofulvin and get medical help right away if you develop severe blistering or peeling skin, signs of jaundice (yellowing of skin or eyes), or signs of a serious allergic reaction like swelling of the face or throat. Rarely, griseofulvin has been linked to low white blood cell counts, liver inflammation, and GI bleeding.
⚠️Warnings & precautions▾
- Serious skin reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis (severe, potentially life-threatening skin blistering and peeling) have been reported. Stop griseofulvin and seek emergency care immediately if this occurs.
- Liver damage: Elevated liver enzymes, hepatitis, and jaundice have been reported and can be serious. Your doctor may monitor your liver during treatment.
- Pregnancy: Griseofulvin is contraindicated in pregnancy. It can cause serious birth defects and embryo toxicity. Cases of conjoined twins and spontaneous abortion have been reported in association with griseofulvin use during pregnancy.
- Not for prophylaxis: Griseofulvin has not been proven safe or effective for preventing fungal infections — it should only be used to treat a confirmed infection.
- Low white blood cell count (granulocytopenia): Griseofulvin should be stopped if this occurs. Report any unusual infections, fever, or chills to your doctor promptly.
🔀What it interacts with▾
Griseofulvin affects the way certain other medications are broken down in the body and can change how well they work.
- Warfarin (blood thinner): Griseofulvin reduces warfarin's anticoagulant effect — dose adjustments may be needed during and after griseofulvin therapy.
- Estrogen-containing birth control pills: Griseofulvin speeds up estrogen breakdown, making oral contraceptives less effective and potentially causing menstrual irregularities. A backup or alternate form of contraception is recommended.
- Cyclosporine: Griseofulvin may lower cyclosporine levels in the blood, reducing its immunosuppressive effect.
- Salicylates (e.g., aspirin): Griseofulvin may reduce salicylate blood levels.
- Barbiturates (e.g., phenobarbital): These can reduce griseofulvin's blood levels and effectiveness — a griseofulvin dose adjustment may be needed.
- Alcohol: Drinking alcohol during treatment can cause nausea, vomiting, flushing, rapid heartbeat (tachycardia), and severe low blood pressure — avoid alcohol while taking griseofulvin.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Do not take griseofulvin if you have porphyria (a rare metabolic disorder) or hepatocellular failure (severe liver failure).
- Do not take griseofulvin if you are allergic to it.
- Do not take griseofulvin if you are pregnant or may become pregnant during treatment — it can cause serious harm to a developing baby.
- Women of childbearing age should use reliable contraception that does not rely solely on estrogen-containing birth control pills during griseofulvin treatment.
- Tell your doctor about all medications you take, especially warfarin, cyclosporine, oral contraceptives, barbiturates, and aspirin-type drugs.
- Griseofulvin is not established as safe or effective for children 2 years of age and younger.
- Tell your doctor if you have any liver problems — griseofulvin is metabolized by the liver and has been associated with liver injury.
- Griseofulvin is not approved for preventing fungal infections — only for treating a confirmed infection.
🚑If you take too much▾
There is limited information about what happens with a griseofulvin overdose. If too much is taken, the medication should be stopped and supportive care provided. If you suspect an overdose, contact a poison control center or emergency services right away.
📡Pharmacodynamics — effects in the body▾
Griseofulvin works specifically against dermatophyte fungi by blocking their ability to divide. It binds to microtubular proteins inside fungal cells, which are essential for mitosis (cell division), stopping the fungus from reproducing. It deposits into keratin-forming cells in skin, hair, and nails — the new tissue that grows in becomes highly resistant to fungal invasion. Griseofulvin has no activity against bacteria or non-dermatophyte fungi.
🔬Pharmacokinetics — how your body processes it▾
Absorption of griseofulvin from the gut varies considerably between individuals — estimated to range from 27% to 72% of an oral dose. Taking it with a high-fat meal significantly increases absorption. After being absorbed, griseofulvin is distributed into keratin precursor cells and stays in skin longer than it does in the bloodstream after the drug is stopped. It is metabolized by the liver and has a variable half-life (the time it takes for blood levels to drop by half) of 9 to 24 hours. About 50% of a dose is excreted in urine within 5 days, mostly as metabolites, and about one-third is excreted in stool; a small amount is also excreted in sweat.
Ultramicrosize Griseofulvin is absorbed approximately one and a half times more efficiently than the conventional microsize formulation, which means a lower total dose of the ultramicrosize form may be used. However, there is currently no evidence that this difference leads to meaningful differences in safety or effectiveness between the two formulations.
📦How to store it▾
Store at 20° to 25°C (68° to 77°F) .
📄 Written from Griseofulvin’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
Supplements & herbs that interact with Griseofulvin
61 supplements and herbal products have documented interactions with Griseofulvin in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 1
- Moderate · 47
- Minor · 13
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Griseofulvin — the kind of thing our pharmacy team would talk through with you at the counter.
How long do I have to take griseofulvin? It seems like a really long time. ▾
Should I take griseofulvin with food? ▾
Can I drink alcohol while on griseofulvin? ▾
Will griseofulvin affect my birth control? ▾
What side effects should I actually call my doctor about versus just wait out? ▾
I'm taking griseofulvin for a nail infection. Do I need to keep using a topical cream too? ▾
Is Griseofulvin available over the counter? ▾
When was Griseofulvin first available? ▾
Who makes Griseofulvin? ▾
💬 Answers drafted from Griseofulvin’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Griseofulvin comes
Griseofulvin is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Griseofulvin tablets and Griseofulvin MICROSIZE tablets treat dermatophyte infections of the skin, hair, and nails not adequately treated by topical therapy
- Ultramicrosize Griseofulvin tablets are indicated for tinea corporis, tinea pedis, tinea cruris, tinea barbae, tinea capitis, and tinea unguium (onychomycosis)
- Ultramicrosize Griseofulvin tablets may be swallowed whole or crushed and sprinkled onto one tablespoon of applesauce and swallowed immediately without chewing
- Griseofulvin MICROSIZE tablets should be taken with a high-fat meal to improve absorption
- All tablet forms must be continued for the full prescribed course — stopping early is likely to cause the infection to return
- Griseofulvin MICROSIZE and Griseofulvin tablets are not established as safe in children 2 years of age and younger
Oral suspension
How this form is used
- Griseofulvin oral suspension treats dermatophyte infections of the skin, hair, and nails not adequately treated by topical therapy
- Griseofulvin oral suspension is used for tinea capitis, tinea corporis, tinea pedis, tinea cruris, tinea barbae, and tinea unguium
- Griseofulvin oral suspension is taken by mouth; dosing frequency is individualized by the prescriber
- Griseofulvin oral suspension should be taken with a fatty meal to improve absorption
- Continue Griseofulvin oral suspension for the full prescribed course — treatment may last weeks to months depending on infection site
- Griseofulvin oral suspension is not established as safe in children 2 years of age and younger
📊 Griseofulvin across the U.S. market
How Griseofulvin appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (4) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Griseofulvin is used
A general measure of how commonly Griseofulvin is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Griseofulvin is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Griseofulvin prescribed? Of the 1,596 medications we measure, Griseofulvin ranks #562 by Medicaid prescriptions — more than 65% of them.
Utilization by Griseofulvin product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
griseofulvin 25 MG/ML Oral Suspension Most dispensed
Summed across the 4 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 239238
griseofulvin 500 MG Oral Tablet
Summed across the 3 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 310600
griseofulvin 250 MG Oral Tablet
Summed across the 3 of 12 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 239239
griseofulvin 125 MG Oral Tablet
Summed across the 2 of 10 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 242831
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Griseofulvin, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 12 of 37 listed Griseofulvin NDCs with Medicaid activity.
🔍 Compare Griseofulvin products
A representative set of FDA-listed product records for Griseofulvin — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Oral suspension | ||||
| 125 mg/5 mL | Oral | Actavis Pharma, Inc. × 3 listings | ANDA | View NDC → |
| 125 mg/5 mL | Oral | Chartwell RX, LLC. × 3 listings | ANDA | View NDC → |
| 125 mg/5 mL | Oral | Cosette Pharmaceuticals, Inc. × 3 listings | ANDA | View NDC → |
| 💊Tablet | ||||
| 125 mg | Oral | Chartwell RX, LLC. × 3 listings | ANDA | View NDC → |
| 250 mg | Oral | Chartwell RX, LLC. × 3 listings | ANDA | View NDC → |
| 500 mg | Oral | Chartwell RX, LLC. × 3 listings | ANDA | View NDC → |
| 125 mg | Oral | Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc × 2 listings | ANDA | View NDC → |
| 250 mg | Oral | Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc × 2 listings | ANDA | View NDC → |
| 500 mg | Oral | Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc × 2 listings | ANDA | View NDC → |
| 125 mg | Oral | Rising Pharmaceuticals, Inc | ANDA | View NDC → |
| 250 mg | Oral | Rising Pharmaceuticals, Inc | ANDA | View NDC → |
| 500 mg | Oral | Rising Pharmaceuticals Inc. | ANDA | View NDC → |
| 250 mg | Oral | Sandoz Inc × 2 listings | ANDA | View NDC → |
| 500 mg | Oral | Sandoz Inc × 2 listings | ANDA | View NDC → |
| 500 mg | Oral | Sigmapharm Laboratories, LLC | ANDA | View NDC → |
| 💊Bulk drug substance | ||||
| 1 kg/kg | — | Chifeng Pharmaceutical Co.,Ltd | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Darmerica, Llc | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Inner Mongolia Glint Pharmaceutical Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Kalchem International inc | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
Showing 36 of 36 products — FDA National Drug Code Directory. See every product, package size and price: browse all 36 Griseofulvin NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Griseofulvin — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Griseofulvin in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Griseofulvin went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 5021 4 dose forms · 8 strengths
-
Dose form (SCDF) Oral Capsule RxCUI 372353No current FDA listingClinical drug / strength (SCD) 250 MGRxCUI 239237 -
Dose form (SCDF) Oral Suspension RxCUI 372354In current FDA listingsClinical drug / strength (SCD) 25 MG/MLRxCUI 239238 -
Dose form (SCDF) Oral Tablet RxCUI 372355In current FDA listings -
Dose form (SCDF) Topical Spray RxCUI 608201No current FDA listingClinical drug / strength (SCD) 10 MG/MLRxCUI 608202
Look up RxCUI 5021 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Griseofulvin is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Griseofulvin belongs to the Tubulin Inhibiting Agent class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 9 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Sandoz Inc is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.